Your browser doesn't support javascript.
The prevalence of antibodies to SARS-CoV-2 among blood donors in China.
Chang, Le; Hou, Wangheng; Zhao, Lei; Zhang, Yali; Wang, Yanbin; Wu, Linfeng; Xu, Tingting; Wang, Lilin; Wang, Juan; Ma, Jian; Wang, Lan; Zhao, Junpeng; Xu, Jing; Dong, Juan; Yan, Ying; Yang, Ru; Li, Yu; Guo, Fei; Cheng, Wenjuan; Su, Yingying; Zeng, Jinfeng; Han, Wei; Cheng, Tong; Zhang, Jun; Yuan, Quan; Xia, Ningshao; Wang, Lunan.
  • Chang L; National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
  • Hou W; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, P.R. China.
  • Zhao L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China.
  • Zhang Y; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Science, Xiamen University, Xiamen, P.R. China.
  • Wang Y; Department of Laboratory, Wuhan Blood Center, Wuhan, P.R. China.
  • Wu L; Confirmation Laboratory for Transfusion Transmitted Disease, Institute of Blood Transfusion of Hubei Province, Wuhan, P.R. China.
  • Xu T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China.
  • Wang L; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Science, Xiamen University, Xiamen, P.R. China.
  • Wang J; Blood Screening Laboratory, Hebei Province Blood Center, Shijiazhuang, P.R. China.
  • Ma J; Shenzhen Blood Center, Shenzhen, P.R. China.
  • Wang L; Department of Laboratory, Wuhan Blood Center, Wuhan, P.R. China.
  • Zhao J; Confirmation Laboratory for Transfusion Transmitted Disease, Institute of Blood Transfusion of Hubei Province, Wuhan, P.R. China.
  • Xu J; Shenzhen Blood Center, Shenzhen, P.R. China.
  • Dong J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China.
  • Yan Y; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Science, Xiamen University, Xiamen, P.R. China.
  • Yang R; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China.
  • Li Y; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health & School of Life Science, Xiamen University, Xiamen, P.R. China.
  • Guo F; Wuhan Blood Center, Wuhan, P.R. China.
  • Cheng W; Shenzhen Blood Center, Shenzhen, P.R. China.
  • Su Y; Wuhan Blood Center, Wuhan, P.R. China.
  • Zeng J; Department of Laboratory, Wuhan Blood Center, Wuhan, P.R. China.
  • Han W; Confirmation Laboratory for Transfusion Transmitted Disease, Institute of Blood Transfusion of Hubei Province, Wuhan, P.R. China.
  • Cheng T; National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China.
  • Zhang J; Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, P.R. China.
  • Yuan Q; Department of Transfusion Research, Wuhan Blood Center, Wuhan, P.R. China.
  • Xia N; Department of Laboratory, Wuhan Blood Center, Wuhan, P.R. China.
  • Wang L; Confirmation Laboratory for Transfusion Transmitted Disease, Institute of Blood Transfusion of Hubei Province, Wuhan, P.R. China.
Nat Commun ; 12(1): 1383, 2021 03 02.
Article in English | MEDLINE | ID: covidwho-1114711
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
In this study, we investigate the seroprevalence of SARS-CoV-2 antibodies among blood donors in the cities of Wuhan, Shenzhen, and Shijiazhuang in China. From January to April 2020, 38,144 healthy blood donors in the three cities were tested for total antibody against SARS-CoV-2 followed by pseudotype SARS-CoV-2 neutralization tests, IgG, and IgM antibody testing. Finally, a total of 398 donors were confirmed positive. The age- and sex-standardized SARS-CoV-2 seroprevalence among 18-60 year-old adults (18-65 year-old in Shenzhen) was 2.66% (95% CI 2.24%-3.07%) in Wuhan, 0.033% (95% CI 0.0029%-0.267%) in Shenzhen, and 0.0028% (95% CI 0.0001%-0.158%) in Shijiazhuang, respectively. Female sex and older-age were identified to be independent risk factors for SARS-CoV-2 seropositivity among blood donors in Wuhan. As most of the population of China remained uninfected during the early wave of the COVID-19 pandemic, effective public health measures are still certainly required to block viral spread before a vaccine is widely available.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article